Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC
Key facts
- Who runs it
- Università degli Studi di Ferrara
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2/3
- People taking part
- 20 people, planned
- Started
- 1 Mar 2025
- Planned end
- Jul 2026
- Type of study
- Interventional
- Treatments tested
- salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)
- Record updated
- 7 February 2025
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- • Age > 18, < 90 years; Non-intubated critically ill patients with AHRF due to pneumonia (diagnosis is based on the presence of infiltrates on chest X-ray and the onset of clinical signs of infection less than 7 days earlier); PaO2/FiO2 ≤ 300 mmHg; Patients receiving oxygen therapy
Who cannot take part
- • Age < 18 years; Hypercapnia (PaCO2 > 50 mmHg); Hemodynamic instability (Systolic blood pressure < 90 mmHg or Mean arterial pressure < 60 or high dose of vasoactive drugs); Tachycardia or tachyarrhythmia (HR > 130 b/min); Known allergy or intolerance to salbutamol; Patient has received inhaled therapy with short-acting beta 2 agonists < 8 hours before or with long-acting beta 2 agonists < 24 hours before; Acute exacerbation of COPD or bronchial asthma; Cardiogenic pulmonary edema; GCS ≤ 12; Contraindication for EIT (e.g. ICD); Pregnancy; Patient refuses to participate
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Acute respiratory failure or pneumonia
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a prospective physiological interventional study that assess the feasibility and safety of administering salbutamol using a vibrating mesh nebulizer during HFNC in patients with acute hypoxemic respiratory failure (AHRF). We evaluate whether this method of salbutamol delivery can reduce inspiratory effort and improve global and regional lung ventilation in AHRF patients. To achieve this, the study will record and analyze the following: esophageal pressure (Pes) curves, global and regional tidal volumes, minute ventilation, and changes in global and regional lung ventilation assessed through Electrical Impedance Tomography (EIT).
The group in the trial
- SalbutamolTreatment being tested
All patients will received ventilatory support with HFNC by adjusting gas flows to 30 L/min with 100% relative humidity, heated to 37 C, adjusting FiO2 levels to maintain SpO2 between 92 and 96%. After 20 min, each patient remaining on ventilatory support with HFNC will receive administration of salbutamol 2.5 mg via the vibrating mesh nebulizer (VMN) (Aerogen Solo®, Aerogen Ltd., Galway, Ireland) positioned immediately downstream of the humidification chamber of the HFNC system, using the dedicated connector.
Treatment: salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Physiological Effects of Nebulized Salbutamol in Patients With Acute Respiratory Failure During HFNC
- Criteria questions
- Built from NCT06815679, who can take part
- Record updated
- 7 February 2025